Is higher income and educational status associated with poorer outcome in patients with Hodgkin's disease?

European Journal of Haematology

Volumn 73, Issue 5, 2004, Pages 318-324

  Holzner, Bernhard ^a   Fischhofer, Martina ^a,b   Kemmler, Georg ^a   Kopp, Martin ^a   Sperner Unterweger, Barbara ^a   Krugmann, Jens ^a   Dirnhofer, Stephan ^c   Greil, Richard ^a,b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Hodgkin's disease; Overall survival; Relapse free survival; Socioeconomic status

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENETIC ANALYSIS; HODGKIN DISEASE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT EDUCATION; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SAMPLING; SOCIAL SUPPORT; SOCIOECONOMICS; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; EDUCATIONAL STATUS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; INCOME; MIDDLE AGED; RECURRENCE; SOCIOECONOMIC FACTORS; SURVIVAL RATE; VIRAL MATRIX PROTEINS;

EID: 5344235363     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00315.x     Document Type: Article

References (28)

1. MACKILLOP WJ, ZHANG-SOLOMONS J, GROOME PA, PASZAT L, HOLOWALY E. Soioeconomic status and cancer survival in Ontario. J Clin Oncol 1997;15:1680-1689.
2. EDWARDS DM JONES J. Incidence of and survival from upper aerodigestive tract cancer in the UK: the influence of deprivation. Eur J Cancer 1999;35:968-972.
3. COLEMAN MP, BABB P, SLOGGETT A, QUINN M, DE STAVOLA B. Socioeconomic inequalities in cancer survival in England and Wales. Cancer 2001;91:208-216.
4. BOYD C, ZHANG-SALOMONS JY, GROOME PA, MACKILLOP WJ. Associations between community income and cancer survival in Ontario, Canada, and United States. J Clin Oncol 1999;17:2244-2255.
5. SCHRIJVERS CTM, MACKENBACH JP, LUTZ JM, et al. Deprivation, stage at diagnosis, and cancer survival. Int J Cancer 1995;63:324-329.
6. MUSTARD CA, FROHLICH N. Socioeconomic status and the health of the population. Med Care 1994;33(Suppl.):43-54.
7. GREIL R, HOLZNER B, KEMMLER G, et al. Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. Eur J Cancer 1999;35:5, 698-706.
8. TURA S, MOZZO P, ZINZANI PL, et al. Hodgkin's disease (HD): a historical perspective. Eur J Cancer 1986;22a:1315-1323.
9. SIEBER M, TESCH H, PFISTNER B, et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002;20:476-484.
10. DUEHMKE E, FRANKLIN J, PFREUNDSCHUH M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:2905-2914.
11. DIEHL V, FRANKLIN J, HASENCLEVER D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998;16:3810-3821.
12. Statistik Austria. Statistisches Jahrbuch. Vienna: Statistik Austria, 2003.
13. COX DR, OAKES D. Analysis of Survival Data. New York: Chapman and Hall, 1984.
14. RUEFFER JU, SCHILLER P, SIEBER M, BREUER K, FRANKLIN J, JOSTING A, WOLF J, DIEHL V. Hodgkin's lymphoma in the elderly - experience of the GHSG. Leuk Lymphoma 2001;42(Suppl. 2): 103 (Abstract P230).
15. MUELLER N, EVANS A, HARRIS NL, COSTOCK GW, JELLUM E, MAGNUS K, ORENTREICH N, POLK BF, VOGELMAN J. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989;320:689-695.
16. ANAGNOSTOPOULOS I, HERBST H, NIEDOBITEK G, STEIN H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma by combined southern blot and in situ hybridization. Blood 1989;74:810-816.
17. MORENTE MM, PIRIS MA, ABRAIRA V, et al. Adverse clinical autcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, High KI 67 proloferation index and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997;90:2429.
18. MURRAY P, BILLINGHAM L, HASSAN H, et al. Effect of Epstein-Barr Virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 1999;94:442-447.
19. MONTALBAN C, ABRAIRA V, MORENTE M, et al. Epstein-Barr virus-latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin's disease treated with chemotherapy. Leuk Lymphoma 2000;39:563-572.
20. NARESH KN, JOHNSON J, SRINIVAS V, et al. Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells. Ann Oncol 2000;11:91-96.
21. GLAVINA-DURDOV M, JAKIC-RAZUMOVIC J, CAPKUN V, MURRAY P. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer 2001;84:1227-1234.
22. KRUGMANN J, TZANKOV A, GSCHWENDTNER A, FISCHHOFER M, GREIL R, FEND F, DIRNHOFER S. Longer failure free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single institution study. Mod Pathol 2003;16:566-573.
23. CLARKE CA, GLASER SL, DORFMAN RF, MANN R, DIGIUSEPPE JA, PREHN AW, AMBINDER RF. Epstein-Barr virus and survival after Hodgkin's disease in a population-based series of women. Cancer 2001;91:1579-1587.
24. ARMSTRONG AA, LENNARD A, ALEXANDER FE, ANGUS B, PROCTOR SJ, ONIONS DE, JARRETT RF. Prognostic significance of Epstein-Barr virus association in Hodgkin's disease. Eur J Cancer 1994;30A:1045-1046.
25. ENBLAD G, SANDVEJ K, LENNETTE E, SUNDSTROMK C, KLEIN G, GLIMELIUS B, PALLESEN G. Lach of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. Int J Cancer 1997;72:394-397.
26. AXDORPH U, PORWIT-MACDONALD A, SJOBERG J, GRIMFORS G, EKMAN M, WANG W, BIBERFELD P, BJORKHOLM M. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum1 factors and blood lymphocyte function. Br J Cancer 1999;81:1182-1187.
27. VON WASIELEWSKI R, WIEBUSCH A, MENGEL M, FRANKLIN J, SCHILLER P, FISCHER R, HÜBNER K, HANSMANN ML, DIEHL V, GEORGII A. Clinical relevance of EBV-detection in Hodgkin's disease. Leuk Lymphoma 2001;42(Suppl. 2):82 (Abstract P170).
28. FLAVELL K, CONSTANDINOU C, LOWE D, et al. Effect of material deprivation on Epstein-Barr virus infection in Hodgkin's disease in the West Midlands. Br J Cancer 1999;80:604-608.